An investigator initiated, randomized, double-blind, multi-center, clinical trial designed to test the primary null hypothesis that warfarin therapy will not reduce the frequency of death or ischemic stroke recurrence by 30% compared with aspirin therapy. The trial will also test that the rate of death and recurrent stroke with warfarin will not be 50% lower in one year compared with aspirin therapy; there will be no differences between the two therapies in the frequency of recurrence by stroke severity or subtype, race or sex.
Showing the most recent 10 out of 753 publications